Free exam prep

CARN-AP Certified Addictions Registered Nurse Advanced Practice

11.3 Prescription Drug Monitoring Programs (PDMP) & Urine Drug Testing (UDT) Interpretation

Q: An APRN receives definitive LC-MS/MS urine drug test results for a 35-year-old patient maintained on sublingual buprenorphine/naloxone 16 mg/4 mg daily for opioid use disorder. The quantitative report displays: Buprenorphine: >5,000 ng/mL; Norbuprenorphine: <5 ng/mL (below limit of quantification); Creatinine: 140 mg/dL. How should the APRN interpret these toxicological findings from a biochemical perspective?

The findings represent direct specimen tampering ('pill spiking'), where the patient introduced the medication directly into the urine cup without in vivo hepatic metabolism.. When buprenorphine is ingested and absorbed in vivo, it undergoes extensive first-pass hepatic N-dealkylation by cytochrome P450 3A4 (CYP3A4) to produce its primary metabolite, norbuprenorphine. In an adherent patient who consumed the medication, both parent buprenorphine and norbuprenorphine are present in urine, with norbuprenorphine concentrations typically rivaling or exceeding parent drug levels. A massive parent buprenorphine level (>5,000 ng/mL) in the complete absence of norbuprenorphine proves that the tablet or film was dissolved directly into the urine specimen ('cup/pill spiking') to mimic compliance, as in vivo hepatic metabolism is biologically required to generate norbuprenorphine.

Q: A 29-year-old patient enrolled in an office-based buprenorphine program presents for a routine follow-up visit. The clinic performs a rapid, point-of-care 12-panel immunoassay cup test. The 'Opiate' test strip displays a negative result (no line), while the buprenorphine test strip is positive. The patient appears clinically stable with no signs of intoxication or withdrawal. What does the negative 'Opiate' immunoassay result indicate?

The negative opiate result is completely normal and expected, because standard point-of-care opiate immunoassays detect natural phenanthrene opioids (morphine and codeine) and do not detect synthetic thebaine derivatives like buprenorphine.. Standard rapid 'Opiate' immunoassay screens are specifically calibrated to detect natural opium alkaloids—namely morphine and codeine—and semi-synthetics at high concentrations. They have zero cross-reactivity with synthetic opioids such as buprenorphine, fentanyl, or methadone. A patient who is maintained exclusively on buprenorphine will naturally and appropriately test negative on a standard 'Opiate' immunoassay strip. Buprenorphine can only be detected via a dedicated buprenorphine immunoassay or definitive chromatography (LC-MS/MS).

Q: An APRN queries the state Prescription Drug Monitoring Program (PDMP) for an established patient receiving buprenorphine/naloxone 16 mg daily. The PDMP report reveals that three days ago, an outside primary care physician issued a 30-day prescription for alprazolam 1 mg twice daily, and another urgent care provider issued a 7-day supply of oxycodone 5 mg, both of which were filled at a retail pharmacy using cash. What is the most appropriate immediate clinical action by the APRN?

Engage the patient in a non-judgmental, curiosity-based dialogue regarding the recent prescriptions, assess for unaddressed pain or distress, co-prescribe naloxone, and coordinate care with the outside prescribers.. When encountering high-risk PDMP findings—such as concurrent opioid and benzodiazepine prescriptions, overlapping prescribers, or cash payments—the APRN must adhere to ethical clinical governance. Abrupt discharge or unilateral abandonment violates non-abandonment principles and dramatically escalates the patient's risk of fatal overdose. The APRN must initiate a calm, non-judgmental conversation ('I noticed these prescriptions on the state monitoring system; help me understand what was occurring...'), assess for acute physical trauma or unmanaged psychiatric symptoms, co-prescribe naloxone immediately due to the extreme danger of combined opioid-benzodiazepine respiratory depression, and contact the external providers to coordinate care.

Q: A 44-year-old patient diagnosed with Major Depressive Disorder and Alcohol Use Disorder in remission presents for a routine visit. The patient takes prescribed bupropion XL 300 mg daily and sertraline 100 mg daily. A rapid point-of-care urine drug immunoassay screen returns positive for amphetamines. The patient vehemently denies using illicit stimulants, Adderall, or diet medications. What is the most appropriate next clinical step by the APRN?

Recognize that bupropion is a well-documented chemical cross-reactant that causes false-positive amphetamine immunoassays, and order definitive LC-MS/MS confirmatory testing before taking clinical action.. Point-of-care urine immunoassays are presumptive qualitative tests vulnerable to chemical cross-reactivity. Bupropion (Wellbutrin) possesses a phenethylamine-like core structure that frequently cross-reacts with the antibodies used in commercial amphetamine immunoassay strips, producing a well-documented false-positive result. Other common cross-reactants for amphetamines include pseudoephedrine, labetalol, and ranitidine. The APRN must recognize this pharmacological phenomenon, reassure the patient, and order definitive confirmatory testing via gas chromatography-mass spectrometry (GC-MS) or liquid chromatography-tandem mass spectrometry (LC-MS/MS), which definitively separates and quantifies true amphetamines from bupropion metabolites.

Key Takeaways

Prescription Drug Monitoring Programs (PDMP) track controlled substance dispensations to identify high-risk co-prescribing (≥50-90 MME/day, opioid-benzodiazepine overlap) and multi-prescriber patterns.
PDMP discrepancies must be approached with curiosity-based, non-judgmental clinical communication—never with punitive discharge or treatment abandonment.
Urine drug testing (UDT) immunoassays are rapid qualitative screens prone to false positives (e.g., bupropion for amphetamine) and blind spots (missing synthetic opioids like fentanyl, methadone, and buprenorphine).
Confirmatory testing (GC-MS / LC-MS/MS) provides definitive quantitative identification: 6-monoacetylmorphine (6-MAM) confirms heroin use, while parent buprenorphine without norbuprenorphine proves pill spiking.
Clinical governance demands using UDT as a diagnostic and therapeutic safety tool to assess adherence and guide harm reduction, never as an interrogation or punitive weapon.

Last updated: September 2026

11.3 Prescription Drug Monitoring Programs (PDMP) & Urine Drug Testing (UDT) Interpretation

Core Clinical Competency: The Advanced Practice Registered Nurse (APRN) must synthesize electronic Prescription Drug Monitoring Program (PDMP) surveillance data and advanced toxicological testing methodologies (point-of-care immunoassay vs. definitive mass spectrometry) to monitor patient safety, detect metabolic divergence, identify specimen tampering, and deliver ethical, non-punitive addiction care.

1. Prescription Drug Monitoring Programs (PDMP): Clinical Governance & Surveillance

Prescription Drug Monitoring Programs (PDMPs) are state-administered electronic databases that collect, monitor, and analyze designated controlled substance (Schedules II–V) dispensations submitted by outpatient retail and mail-order pharmacies. Most state systems are interconnected through national data-sharing hubs (e.g., PMP InterConnect), enabling prescribers to review controlled substance histories across state lines.

Clinical Governance & Mandates for PDMP Query

Best practice guidelines established by the CDC, ASAM, and state licensing boards dictate specific clinical checkpoints for mandatory PDMP review:

Initial Evaluation: Prior to initiating any controlled substance (opioids, stimulants, benzodiazepines, buprenorphine).
Periodic Surveillance: At least quarterly (every 90 days) during chronic therapy, or before every early refill request, unexplained dose escalation, or signs of intoxication/aberrant behavior.
Transitions of Care: Upon hospital discharge, emergency department evaluation, or transfer between clinics.

High-Risk PDMP Indicators ("Red Flags")

PDMP Risk Stratification & Clinical Action:

[PDMP Query Performed]
           │
  ┌────────┴────────────────────────┬────────────────────────┐
  ▼                                 ▼                        ▼
[High Cumulative MME]     [Dangerous Combinations]   [Multi-Provider / Pharmacy]
• ≥50 MME/day: Caution    • Opioids + Benzodiazepines • Multiple prescribers/pharmacies
• ≥90 MME/day: High Risk  • Opioids + Sedatives/Carisoprodol • Cash fills despite insurance
  │                                 │                        │
  └─────────────────────────────────┼────────────────────────┘
                                    ▼
                   [Clinical Action Required]
                   • Co-prescribe Naloxone immediately
                   • Non-punitive exploratory dialogue
                   • Evaluate for unaddressed pain or OUD
                   • Offer MOUD (buprenorphine/methadone)

High Cumulative Morphine Milligram Equivalents (MME):
- ≥50 MME/day: Threshold for heightened caution; risk of fatal overdose doubles compared to <20 MME/day. Re-evaluate pain etiology and increase monitoring frequency.
- ≥90 MME/day: Substantial overdose mortality risk. Federal guidelines advise against titrating beyond 90 MME/day without explicit clinical justification, pain specialist consultation, and mandatory co-prescribing of take-home naloxone.
Dangerous Pharmacological Combinations:
- Concurrent Opioids and Benzodiazepines: Combined ingestion accounts for nearly 30% of prescription opioid overdose deaths. Synergistic GABAA and mu-opioid receptor stimulation causes profound, uncoupled hypoventilation.
- Opioids + Sedatives/Hypnotics or Muscle Relaxants (Carisoprodol/Soma): The classic 'Holy Trinity' (opioid + benzodiazepine + carisoprodol) carries severe abuse and fatal toxicity liability.
Multi-Prescriber & Multi-Pharmacy Dispensations ("Doctor Shopping"): Receiving controlled substance prescriptions from multiple unaffiliated prescribers or filling at multiple geographically dispersed pharmacies within rolling 30- to 90-day intervals.
Cash Transactions: Paying out-of-pocket cash for expensive controlled substances despite possessing active commercial or Medicaid/Medicare health insurance coverage.

The Ethical, Non-Punitive Approach to PDMP Discrepancies

When a PDMP report reveals undisclosed controlled substances, overlapping prescriptions, or early fills, the APRN must never engage in punitive discharge, accusatory confrontation, or patient abandonment. Abrupt discharge or unilateral deprescribing violates nursing ethics and dramatically spikes the patient's risk of fatal overdose by forcing them into the unregulated, fentanyl-contaminated illicit street market.

Patient Communication Framework for PDMP Discrepancies:

Step 1: Curiosity-Based, Neutral Opening
"I checked the state prescription monitoring database before our appointment today, as I do for all my patients to ensure safety. I noticed a prescription for oxycodone filled two weeks ago from an urgent care clinic. Help me understand what was going on with your health around that time?"

Step 2: Objective Clinical Exploration
Assess for acute physical trauma, unmanaged chronic pain flare, severe withdrawal distress, psychiatric crisis, or escalating substance use disorder.

Step 3: Therapeutic Collaborative Intervention
Coordinate with the external prescriber, provide overdose education, co-prescribe naloxone, adjust buprenorphine dosing to resolve unmanaged cravings, increase clinic contact frequency, and utilize blister packaging.

2. Urine Drug Testing (UDT): Immunoassay vs. Definitive Chromatography

Urine drug testing is a core diagnostic monitoring modality in addiction medicine. However, misinterpreting toxicological findings can lead to erroneous diagnostic conclusions, unjustified treatment terminations, or missed opportunities to identify relapse.

| Feature | Point-of-Care / Rapid Immunoassay (IA) | Gas Chromatography-Mass Spectrometry (GC-MS) / Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) | | :--- | :--- | :--- | | | Methodology | Competitive antibody-antigen binding assay using predetermined qualitative threshold cutoffs. | Physical molecular separation via chromatographic column followed by mass-to-charge ($m/z$) spectral fragmentation analysis. | | Turnaround Time | Immediate (5 to 15 minutes); available in-clinic. | 24 to 72 hours; requires specialized reference laboratory instrumentation. | | Result Type | Qualitative ONLY (Presumptive Positive or Negative). | Quantitative (reports exact nanogram/milliliter [ng/mL] concentrations of specific molecules). | | Sensitivity / Specificity | Prone to false positives (antibody cross-reactivity) and false negatives (blind spots). | Gold Standard: Near 100% sensitivity and specificity. Eliminates cross-reactivity. | | Synthetic Opioid Detection | BLIND SPOT: Fails to detect synthetic opioids (fentanyl, buprenorphine, methadone) unless specialized dedicated assays are ordered. | Detects and quantifies all synthetic opioids, analogues, parent drugs, and specific metabolites. | | Clinical Utility | Rapid initial triage; guides immediate conversation during appointment. | Confirmatory testing for all unexpected positive or negative screens; forensic validation. |

3. Immunoassay Cross-Reactivity: Common False Positives & Critical Blind Spots

Documented Immunoassay Cross-Reactions (False Positives)

Immunoassays rely on antibodies that target specific chemical pharmacophores. Structural mimics frequently bind to the test antibodies, generating false-positive presumptive screens:

Common Immunoassay Cross-Reactivities:

Presumptive Positive ◄── Cross-Reacting Therapeutic Medication
─────────────────────────────────────────────────────────────────────────────
Amphetamines         ◄── Bupropion (Wellbutrin), Pseudoephedrine, Labetalol,
                         Ranitidine, Trazodone, Phenylephrine, Vicks VapoInhaler
PCP (Phencyclidine)  ◄── Dextromethorphan (DXM), Diphenhydramine (Benadryl),
                         Tramadol, Venlafaxine (Effexor)
Opiates (Standard)   ◄── Fluoroquinolones (Levofloxacin, Ciprofloxacin, Ofloxacin),
                         Rifampin, Poppy seed ingestion (dietary morphine/codeine)
Benzodiazepines      ◄── Sertraline (Zoloft), Oxaprozin (Daypro)
Cannabinoids (THC)   ◄── Efavirenz, NSAIDs (historical/rare), Proton Pump Inhibitors

Critical Immunoassay Blind Spots (False Negatives)

The standard point-of-care "Opiate" immunoassay cup utilizes antibodies calibrated to detect natural phenanthrene opium alkaloids: Morphine and Codeine (and semi-synthetics such as hydrocodone or hydromorphone at high concentrations).

The Synthetic Opioid Blind Spot: Standard opiate screens DO NOT DETECT synthetic opioids or distinct chemical classes:
- Fentanyl (synthetic phenylpiperidine)
- Buprenorphine (semi-synthetic thebaine derivative)
- Methadone (synthetic diphenylheptane)
- Oxycodone / Oxymorphone (frequently missed on standard opiate screens; requires a dedicated oxycodone antibody assay)
- Tramadol, Tapentadol, Meperidine
Clinical Implication: A patient maintained on buprenorphine who produces a "Negative Opiate" result on a standard rapid cup is exhibiting an entirely normal, expected finding; buprenorphine requires a specific buprenorphine immunoassay. Conversely, a patient actively overdosing on illicit fentanyl will test "Negative for Opiates" on standard screens unless a dedicated fentanyl immunoassay is performed.

4. Metabolic Cascades: Differentiating Ingestion from Specimen Tampering

Definitive chromatography (LC-MS/MS) separates parent drugs from their in vivo hepatic metabolites. Understanding these metabolic pathways allows the APRN to confirm ingestion, detect illicit heroin, and identify specimen adulteration.

Opioid Hepatic Metabolic Pathways:

Heroin (Diacetylmorphine)
   │  (Half-life 3-5 min)
   ▼
6-Monoacetylmorphine (6-MAM)  ──► [PATHOGNOMONIC FOR HEROIN USE!]
   │  (Half-life 30-40 min, urine window 6-24 hours)
   ▼
Morphine ◄── Codeine (10% via CYP2D6)
   │
   ▼ (Glucuronidation)
Morphine-3-glucuronide & Morphine-6-glucuronide
   │ (Minor pathway)
   ▼
Hydromorphone (trace)

Heroin vs. Prescription Opiate Identification

6-Monoacetylmorphine (6-MAM): Heroin is rapidly deacetylated in blood and tissues to 6-MAM, which is subsequently hydrolyzed to morphine. The presence of 6-MAM in urine is conclusive and pathognomonic for illicit heroin use. Because 6-MAM has a short half-life (urinary detection window only 6 to 24 hours), its absence does not exclude heroin; a sample showing high morphine without 6-MAM could represent remote heroin use, pharmaceutical morphine, or high-dose codeine.
Codeine Metabolism: Codeine is metabolized via hepatic CYP2D6 into morphine (approx. 10%) and via CYP3A4 into norcodeine. In a patient taking prescribed codeine, urine chromatography shows high concentrations of codeine accompanied by lower concentrations of morphine. If morphine concentration significantly exceeds codeine, or if codeine is absent, the patient ingested morphine or heroin, not codeine alone.

Buprenorphine Metabolism & The "Pill Spiking" Phenomenon

Sublingually administered buprenorphine undergoes extensive hepatic N-dealkylation primarily via CYP3A4 and glucuronidation (UGT1A1, UGT2B7) into its primary active metabolite, Norbuprenorphine.

Buprenorphine Hepatic Metabolic Cascade:

[Prescribed Sublingual Buprenorphine]
                 │
                 ▼  (Hepatic In Vivo CYP3A4 Metabolism)
        [Norbuprenorphine]
                 │
                 ▼  (Renal Excretion)
[Urine LC-MS/MS: BOTH Buprenorphine AND Norbuprenorphine Present]

LC-MS/MS Toxicological Finding	Clinical Interpretation & Biochemical Mechanism
Buprenorphine (+) & Norbuprenorphine (+)	Normal Adherence: The patient took the medication sublingually. Hepatic CYP3A4 metabolized the parent compound into norbuprenorphine in vivo. Norbuprenorphine levels frequently equal or exceed parent drug levels.
Buprenorphine (Very High >1,000–10,000 ng/mL) & Norbuprenorphine (NEGATIVE or <10 ng/mL)	SPECIMEN TAMPERING ("PILL SPIKING"): The patient shaved, crushed, or dissolved a portion of their sublingual tablet or film directly into the urine collection cup! Because the drug never passed through a living human liver, no hepatic CYP3A4 metabolism occurred, resulting in massive parent drug concentration and zero norbuprenorphine.
Buprenorphine (-) & Norbuprenorphine (-)	Non-Adherence / Diversion: The patient is not taking the medication, or the urine sample was substituted with synthetic urine or another individual's drug-free urine.
Buprenorphine (Trace/Low) & Norbuprenorphine (High)	Delayed Collection / Normal Elimination: Indicates remote dosing (e.g., 24 to 48+ hours prior to sample collection), where the parent drug has largely cleared while the metabolite remains.

Methadone Metabolism & Tampering

Methadone is metabolized in the liver by CYP3A4, CYP2B6, and CYP2C19 into EDDP (2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine).

Adherent Ingestion: Urine contains both parent methadone and EDDP.
Spiked Cup: Massive methadone concentrations with undetectable EDDP indicates direct tampering (dropping liquid methadone into the collection cup).

5. Clinical Governance Matrix: Managing Discrepant UDT Results

Discrepant Finding	Immediate Clinical Action	Follow-Up Strategy
Unexpected Positive Immunoassay	Do NOT accuse or penalize. Order definitive LC-MS/MS confirmation. Review medication list for cross-reacting agents (e.g., bupropion for amphetamines).	Withhold punitive changes pending mass spectrometry confirmation. Discuss findings collaboratively.
Pill Spiking Confirmed (Parent (+) / Metabolite (-))	Explore barriers to adherence non-judgmentally: "The laboratory analysis shows that the medication was added directly to the cup without passing through your body. What challenges are you experiencing with taking your medication?"	Evaluate for medication diversion, fear of withdrawal, or lost/stolen doses. Consider transitioning to observed dosing or long-acting injectable buprenorphine (Sublocade).
Unexpected Negative for Prescribed Drug	Confirm whether an appropriate assay was utilized (e.g., dedicated buprenorphine or fentanyl assay vs. standard opiate screen). Check urine creatinine and specific gravity for specimen dilution.	Assess for medication discontinuation, financial barriers, adverse side effects, or diversion. Re-establish therapeutic alliance.

Test Your Knowledge

An APRN receives definitive LC-MS/MS urine drug test results for a 35-year-old patient maintained on sublingual buprenorphine/naloxone 16 mg/4 mg daily for opioid use disorder. The quantitative report displays: Buprenorphine: >5,000 ng/mL; Norbuprenorphine: <5 ng/mL (below limit of quantification); Creatinine: 140 mg/dL. How should the APRN interpret these toxicological findings from a biochemical perspective?

The findings indicate rapid ultrarapid hepatic CYP3A4 metabolism, clearing norbuprenorphine before renal elimination.

The findings confirm optimal patient adherence with peak steady-state sublingual absorption occurring within 1 hour of specimen voiding.

The findings represent direct specimen tampering ('pill spiking'), where the patient introduced the medication directly into the urine cup without in vivo hepatic metabolism.

The findings demonstrate high renal clearance of buprenorphine driven by severe systemic metabolic acidosis.

Test Your Knowledge

A 29-year-old patient enrolled in an office-based buprenorphine program presents for a routine follow-up visit. The clinic performs a rapid, point-of-care 12-panel immunoassay cup test. The 'Opiate' test strip displays a negative result (no line), while the buprenorphine test strip is positive. The patient appears clinically stable with no signs of intoxication or withdrawal. What does the negative 'Opiate' immunoassay result indicate?

The patient has been secretly taking high doses of illicit heroin, which suppressed the antibody reaction on the test strip.

The buprenorphine is competitively binding to the opiate antibody, displacing morphine and causing an assay malfunction.

The patient is experiencing acute renal failure resulting in an inability to excrete opioid metabolites into the urine.

The negative opiate result is completely normal and expected, because standard point-of-care opiate immunoassays detect natural phenanthrene opioids (morphine and codeine) and do not detect synthetic thebaine derivatives like buprenorphine.

Test Your Knowledge

An APRN queries the state Prescription Drug Monitoring Program (PDMP) for an established patient receiving buprenorphine/naloxone 16 mg daily. The PDMP report reveals that three days ago, an outside primary care physician issued a 30-day prescription for alprazolam 1 mg twice daily, and another urgent care provider issued a 7-day supply of oxycodone 5 mg, both of which were filled at a retail pharmacy using cash. What is the most appropriate immediate clinical action by the APRN?

Engage the patient in a non-judgmental, curiosity-based dialogue regarding the recent prescriptions, assess for unaddressed pain or distress, co-prescribe naloxone, and coordinate care with the outside prescribers.

Immediately discharge the patient from the addiction practice for violating the controlled substance agreement and report the patient to local law enforcement for doctor shopping.

Abruptly discontinue the buprenorphine prescription to prevent drug interactions and refuse to see the patient until they provide a clean drug screen.

Disregard the PDMP report because buprenorphine has a ceiling effect on respiratory depression that completely neutralizes any risk associated with benzodiazepines.

Test Your Knowledge

A 44-year-old patient diagnosed with Major Depressive Disorder and Alcohol Use Disorder in remission presents for a routine visit. The patient takes prescribed bupropion XL 300 mg daily and sertraline 100 mg daily. A rapid point-of-care urine drug immunoassay screen returns positive for amphetamines. The patient vehemently denies using illicit stimulants, Adderall, or diet medications. What is the most appropriate next clinical step by the APRN?

Confront the patient regarding illicit methamphetamine use and mandate intensive outpatient stimulant treatment before continuing antidepressant pharmacotherapy.

Recognize that bupropion is a well-documented chemical cross-reactant that causes false-positive amphetamine immunoassays, and order definitive LC-MS/MS confirmatory testing before taking clinical action.

Discontinue the sertraline immediately because selective serotonin reuptake inhibitors metabolize into methamphetamine in the renal tubules.

Instruct the patient to drink two liters of cranberry juice and repeat the point-of-care immunoassay in two hours to acidify the urine.

Up Next

12.1 APRN Scope of Practice, Prescriptive Authority & Collaborative Practice Regulations

Chapter 12: APRN Scope of Practice, Ethical Foundations, Harm Reduction & Research Literacy

Certified Addictions Registered Nurse - Advanced Practice

1Introduction: The CARN-AP Examination & Foundations of Advanced Addictions Practice

2Chapter 1: Opioid Use Disorder: Assessment, Overdose Response & Methadone Maintenance

3Chapter 2: Buprenorphine Protocols, Long-Acting Injectables & Naltrexone

4Chapter 3: Alcohol Use Disorder: Neurobiology, Assessment & Acute Withdrawal

5Chapter 4: Medications for Alcohol Use Disorder (MAUD)

6Chapter 5: Stimulant, Sedative-Hypnotic & Synthetic Substance Use Disorders

7Chapter 6: Tobacco and Cannabis Use Disorders: Evidence-Based Pharmacotherapy & Interventions

8Chapter 7: Psychiatric Differential Diagnosis & Medical Mimics in Addictions

9Chapter 8: Co-Occurring Psychiatric Disorders: Integrated Treatment Planning

10Chapter 9: Pain Management in Substance Use Disorders & CDC 2022 Guidelines

11Chapter 10: Perinatal Substance Use, Neonatal Abstinence & Infectious Complications

12Chapter 11: Federal Regulations, Confidentiality & Controlled Substance Prescribing

13Chapter 12: APRN Scope of Practice, Ethical Foundations, Harm Reduction & Research Literacy

14Chapter 13: Stimulant Use Disorder in Depth — Methamphetamine, Withdrawal, Treatment & Harm Reduction

15Chapter 14: Medical Consequences of Alcohol Use — Liver, Heart, Cancer & Nutrition

16Chapter 15: Brief Intervention, Drinking Goals & Recovery Support in Alcohol Use Disorder

17Chapter 16: Tobacco Use Disorder in Depth — Neurobiology, Assessment & Special Populations

18Chapter 17: Cannabis Use Disorder in Depth — Products, Treatment & Policy

19Chapter 18: Other Use Disorders — Inhalants, Hallucinogens, Process Addictions & Prescription/OTC Misuse

20Chapter 19: Educating Patients, Families & the Public (CARN-AP Activity Area III)

21Chapter 20: Consultation, Collaboration & Care Coordination (CARN-AP Activity Area IV)

22Chapter 21: Quality Improvement, Evidence & Leadership in Addictions Nursing (CARN-AP Activity Area V)

CARN-AP Certified Addictions Registered Nurse Advanced Practice

11.3 Prescription Drug Monitoring Programs (PDMP) & Urine Drug Testing (UDT) Interpretation

Key Takeaways

11.3 Prescription Drug Monitoring Programs (PDMP) & Urine Drug Testing (UDT) Interpretation

1. Prescription Drug Monitoring Programs (PDMP): Clinical Governance & Surveillance

Clinical Governance & Mandates for PDMP Query

High-Risk PDMP Indicators ("Red Flags")

The Ethical, Non-Punitive Approach to PDMP Discrepancies

2. Urine Drug Testing (UDT): Immunoassay vs. Definitive Chromatography

3. Immunoassay Cross-Reactivity: Common False Positives & Critical Blind Spots

Documented Immunoassay Cross-Reactions (False Positives)

Critical Immunoassay Blind Spots (False Negatives)

4. Metabolic Cascades: Differentiating Ingestion from Specimen Tampering

Heroin vs. Prescription Opiate Identification

Buprenorphine Metabolism & The "Pill Spiking" Phenomenon

Methadone Metabolism & Tampering

5. Clinical Governance Matrix: Managing Discrepant UDT Results